Welcome To The Mannkind HUB On AGORACOM
Edit this title from the Fast Facts Section
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

UBR: TSX-V

Uragold Discusses Merits of Recent Acquisition from Fancamp

Welcome to Beyond The Press Release a production of AGORACOM in which we take the time to talk to small cap ceo’s and executives about their recent press releases. Bernard Tourillon, Chairman, CEO and Director of Uragold discusses the Conditional Approval from the TSX Venture Regarding the Acquisition of 32 Claims from Fancamp.

Hub On AGORACOM / Corporate Profile / Watch Interview Now!

 

Message: Afrezza sales could be higher than Exubera, says Summer Street

Barney-fife-crop-fix
Rank: [?]
President
Points: [?]
5492
Rating: [?]
Votes: 21 Score: 4.5
  • Currently 4.5/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Afrezza sales could be higher than Exubera, says Summer Street

posted on Jul 16, 13 09:52AM

"Summer Street believes that if approved, sales of MannKind's (MNKD) inhalable insulin Afrezza could be "substantially higher" than Pfizer’s (PFE) Exubera given Afrezza’s ease of use. However, the firm adds that it cannot accurately predict future sales of Afrezza at this time."

http://www.theflyonthewall.com/permalinks/entry.php/MNKD;PFEid1858409/MNKD;PFE-Afrezza-sales-could-be-higher-than-Exubera-says-Summer-Street

New Message

Please login to post a reply

AGORACOM Quick Tips

What Is Twitter? Watch Our 5-Minute Tutorial ... Watch Now

President's D.D.

Here's the latest Griffin report read more

Stock Quote

Hub Leaders